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Methods
Pooled population of patients with Ph+ leukemia
Patient listings were available for all trials in this pooled analysis; however, not all data elements were available for all studies. Duration of treatment varied across studies, and was longer in chronic myeloid leukemia in chronic phase (CML-CP) (median 29 months; range 0-93 months) than in accelerated or blast phase CML (CML-AP/BP) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (median 6 months; range 0-93 months). Treatment duration also was longer in patients with CML-CP treated with first-line dasatinib from DASISION (median 60 months; range 0-73 months) than in CML-CP patients treated following failure of prior imatinib from 034/Dose-optimization (median 30 months; range 0-93 months).
Assessments
Adverse events were graded as follows: Grade 1-asymptomatic; Grade 2-symptomatic, intervention such as diuretics or up to 2 therapeutic thoracenteses indicated; Grade 3-symptomatic and supplemental oxygen, <2 therapeutic thoracenteses, tube drainage, or pleurodesis indicated; Grade 4life-threatening, causing hemodynamic instability or ventilatory support indicated; Grade 5-death related to pleural effusion. Confirmed complete cytogenetic response (CCyR) was defined as 0% Ph+ cells in ≥20 metaphases, partial cytogenetic response (CyR) >0% to 35%, minor CyR >35% to 65%, and minimum CyR >65% to 95%. Major molecular response (MMR) was defined by BCR-ABL1 transcripts ≤0.1% on the International Scale (IS), corresponding to a 3-log reduction from the standardized baseline.
MR 4 was defined by BCR-ABL1 transcripts <0.01% (IS), corresponding to a 4-log reduction from the standardized baseline. MR 4.5 was defined by BCR-ABL1 transcripts ≤0.0032% (IS), corresponding to a 4.5-log reduction from the standardized baseline.
Progression was defined broadly in DASISION as any of the following: doubling of white blood cell (WBC) count to >20×10 9 /L in the absence of complete hematologic response (CHR); loss of CHR; increase in Ph+ bone marrow metaphases to >35%; transformation to CML-AP/BP; or death from any cause. Patients who discontinued who had not died and agreed to follow-up continued to be followed for transformation and survival on a yearly basis for up to 5 years in DASISION. Progression was defined in 034/Dose-optimization as confirmed CML-AP/BP, loss of a previous CHR or major CyR (MCyR), ≥30% increase in Ph+ metaphases, increasing WBC count (recorded by the investigator as a doubling from lowest value to >20,000/µL or an increase by >50,000/µL on 2 assessments performed at least 2 weeks apart), or death from any cause. Patients were followed for overall survival (OS) for a minimum of 7 years, but were not followed for progression-free survival (PFS), after they had discontinued dasatinib.
Of note, DASISION was the sole study included in this analysis that required routine chest Xrays to assess the presence of pleural effusion, including asymptomatic events.
Statistical analyses
Retrospective multivariate analyses were performed to identify potential factors associated with the incidence of pleural effusion. These included race, sex, region, age, dosing schedule (034/Doseoptimization only), exposure to interferon (034/Dose-optimization only), baseline Euro (Hasford) risk scores (DASISION only), BCR-ABL1 levels at 3 months, lymphocytosis, timing of lymphocytosis to onset of pleural effusion, colitis, baseline disease status, baseline hypertension, baseline smoking history, prior autoimmune disease, prior skin rash, prior lung disease, MMR at 12 months, line of therapy, average daily dose, duration of prior TKI therapy, and depth of MR at any time.
Rates of PFS and OS were estimated using Kaplan-Meier analysis. For PFS analysis, patients who discontinued without progression were censored at the time of the last on-study hematologic or cytogenetic evaluation. For OS analysis, patients who had not died were censored on the last date the patient was known to be alive, which included dates after study discontinuation if provided by investigators. CCyR: complete cytogenetic response; CyR: cytogenetic response; MMR: major molecular response, BCR-ABL1 transcripts ≤0.1% on the International Scale (IS) corresponding to a 3-log reduction from a standardized baseline; MR 4.5 : BCR-ABL1 transcripts ≤0.0032% (IS) corresponding to a 4.5-log reduction from a standardized baseline; PCyR: partial cytogenetic response. 
